Home ::> Staff Listings ::> Staff Listing by Name ::> T ::> Philip Teal

STAFF LISTING

Dr. Philip Teal

Sauder Family and HSF of BC&Y Professor of Clinical Stroke Research

Clinical Professor of Neurology
Division of Neurology, Medicine Faculty of Medicine, UBC

Address
#8289 – 2775 Laurel Street

The Gordon and Leslie Diamond Health Care Centre
University of British Columbia
Vancouver BC Canada V5Z 1M9

Tel:  (604) 875-5515
Fax
: (604) 875-5514
Email:

 

Research Interests:

  • Clinical trials in acute stroke therapy

  • Thrombolysis, neuroprotection, interventional stroke therapy

  • Antithrombotic therapy in the management of stroke

  • Stroke prevention and management of risk factors

Professional Training:

  • 1970-1974: Medical school at the University of Alberta

  • 1986-1990: Neurology Residency at the University of British Columbia

  • 1990-1992: Stroke Fellowship at Tufts University, Boston Ma

Academic Positions:

  • 1990-1992: Clinical Instructor, Dept. of Neurology (Tufts University, Boston Ma)

  • 1992-Present: Clinical Professor (Department of Medicine, Division of Neurolgy UBC)

Honours and Awards:

  • E.L Pope Memorial Award in Medicine (1974)

  • Award for Outstanding Grand Medical Rounds (2004)

  • The F.R. Dirks Award for Excellence in Medical Teaching University of British Columbia (2007)

  • Best Doctors in America, Woodward Wright Inc (1998)

  • Best Doctors in Canada (2007)

Board Representations:

  • The Heart and Stroke Foundation of Canada

  • The Canadian Stroke Consortium

  • World Stroke Organization

Publications

Diener HC, Sacco RL, Yusef S, et al including Teal PA. Effects of aspirin plus extended-release dipyridamole versus Clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology Sept 2008;7:875-84 [PubMed]

Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Addition) CHEST 2008;133:630-669S. [PubMed]

Sacco RL, Diener HC, Yusuf S et al including Teal, Philip. Aspirin and Extended-
Released Dipyridamole vs Clopidogrel for Recurrent Stroke
. N Eng J Med 2008;359:1238-51. [PubMed]

Yusuf S, Diener HC, Sacco RL et al including Teal, P. Telmisartan to prevent recurrent Stroke and cardiovascular events. N Engl J Med 2008;359:1225-37. [PubMed]

Woolfenden AR, Wade NK, Tang P, Clamers A, Reid G, Teal PA. Uveitis Associated with Primary Angiitis of the Centreal Nervous System. Can J. Neurol. Sci. 2007;34:81-83. [PubMed]

Muir KW, Teal PA. Why have neuroprotectants failed? Lessons learned from stroke trials. J Neurol. 2005 August 25;[Epub ahead of print]. [PubMed]

Hill MD, Buchan AM, for the CASES Investigators including Teal P Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for stroke effectiveness study. CMAJ 2005;172:1307-12. [PubMed]

Albers GW, Amarenco P, Easeon JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. The seventh ACCP Conference on the Antithrombotic and thrombolytic therapy. CHEST 2004;126:483S-512S. [PubMed]

Caplan LR, Whityk RJ, Glass TA, Tapia J, Pazdera L, Chang HM, Teal P, Dashe JF, Chaves CJ, Breen JC, Vemmos K, Amarenco P, et al. New England Medical Center Posterior Circulation registry. Ann Neurol. 2004;56:389-98. [PubMed]

Teal PA. Recent clinical trial results with antiplatelet therapy implication in stroke prevention. Cerebrovascular Diseases 2004;17 Suppl 3:6-10.

Teal P, Silver FL, Simard D. Safety, Tolerability, and Dose-finding of Repinotan in Acute Stroke. The Canadian Journal of Neuroscience. 2005;32:61-67. [PubMed]

Toole JF, Malinow MR, Chanbless LE et al including Teal PA. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA 2004;291:565-75. [PubMed]

Woolfenden AR, Teal PA, Wade NK, Tang P, Chalmers A, Reid G. CNS Vasculitis Uveitis Syndrome. Canadian J of Neurol Sciences 2004.

Fisher M et al including Teal P for Stroke Therapy Industry Academic Round Table. Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic industry roundtable 3. Stroke 2003;34:1539-1546. [PubMed]

Multiple Contributors including Teal, P. Recommendations for Improving Clinical Trials Design and Endpoint Selection. Stroke Therapy Academic Industry Roundtable II (STAIR II).

Krams J, Lees KR, Hacke W et al. (Teal P Investigator, contributor, steering Committee.) Acute stroke therapy by inhibition of neurtophils (ASTIN) Stroke 2003; 34:2543-2548. [PubMed]

Mahon BR, Nesbit GM, Barnwell SL, Clark W, Marotta TR, Weill A Teal PA, Quershi AI. North America clinical experience with the EKOS MicroLys US infusion catheter for the treatment of embolic stroke. Neurology 2003; 24:534-8. [PubMed]

Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. CHEST February 2001. [PubMed]

Stroke Therapy Academic Industry Roundtable II. Recommendations for clinical trial evaluations of acute stroke therapies. Statement contributor. Stroke 2001;32:1598-1606. [PubMed]

Sinclair SE. Frighetto L. Loewen PS. Sunderji R. Teal P. Fagan SC. Marra CA. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 19(9):927-36, 2001. [PubMed]

Hill, MD, Woolfenden A, Teal P, Buchan AM. Intravenous Alteplase for Stroke: The Canadian Experience. The Stroke Interventionalist 2000; Volume II, Issue 2:5-8.

 

 

 

a place of mind, The University of British Columbia

 

 

 

 

 

Emergency Procedures | Accessibility | Contact UBC | © Copyright The University of British Columbia